IRADIMED CORP
Business
IRadimed Corporation develops, manufactures, markets and distributes non-magnetic MRI-compatible medical devices and related accessories, disposables and services. The company offers MRI-compatible IV infusion pump systems (MRidium 3870 and 3860+), patient vital signs monitoring systems (3880 Monitor), and ferromagnetism detection devices (FMD1). IRadimed sells primarily to hospitals and acute care facilities in the United States through direct sales and internationally through independent distributors.
Summary from 10-K filed 2026-03-06
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 84 | 73 | 66 | 53 | 42 | |
| Cost of revenue | 19 | 17 | 15 | 12 | 10 | |
| Gross profit | 64 | 56 | 50 | 41 | 32 | |
| General and administrative | 18 | 16 | 15 | 11 | 10 | |
| Sales and marketing | 17 | 16 | 12 | 13 | 11 | |
| Research and development | 3 | 3 | 3 | 2 | 2 | |
| Total operating expenses | 38 | 34 | 30 | 26 | 22 | |
| Income from operations | 26 | 22 | 20 | 16 | 10 | |
| Other income, net | 2 | 2 | 2 | 553,104 | 18,605 | |
| Income before provision for income taxes | 28 | 24 | 22 | 16 | 10 | |
| Provision for income tax expense | 6 | 5 | 5 | 3 | 510,816 | |
| Net income | 22 | 19 | 17 | 13 | 9 | |
| Basic (in dollars per share) | 1.77 | 1.52 | 1.36 | 1.02 | 0.76 | |
| Diluted (in dollars per share) | 1.75 | 1.5 | 1.35 | 1.02 | 0.74 | |
| Basic (in shares) | 13 | 13 | 13 | 13 | 12 | |
| Diluted (in shares) | 13 | 13 | 13 | 13 | 13 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 51 | 52 | 50 | 58 | 62 | |
| Accounts receivable, net of allowance for credit losses of $191 as of December 31, 2025, and $274 as of December 31, 2024 | 14 | 11 | 12 | 13 | 5 | |
| Inventory, net | 12 | 10 | 13 | 5 | 4 | |
| Prepaid expenses and other current assets | 5 | 2 | 1 | 630,960 | 1 | |
| Total current assets | 81 | 75 | 76 | 77 | 76 | |
| Property and equipment, net | 24 | 17 | 9 | 2 | 2 | |
| Intangible assets, net | 3 | 3 | 3 | 2 | 1 | |
| Deferred tax asset, net | 94,000 | 3 | 2 | 700,867 | 765,096 | |
| Other assets | 239,000 | 354,000 | 181,449 | 648,672 | 201,325 | |
| Total assets | 109 | 98 | 92 | 86 | 83 | |
| Accounts payable | 2 | 2 | 2 | 2 | 782,903 | |
| Accrued payroll and benefits | 3 | 4 | 3 | 3 | 3 | |
| Warranty reserve | 144,000 | 118,000 | 117,463 | 94,030 | 108,880 | |
| Deferred revenue | 3 | 2 | 3 | 3 | 3 | |
| Other current liabilities | 313,000 | 466,000 | 250,000 | — | 146,435 | |
| Accrued income taxes | 2 | — | 250,041 | — | — | |
| Total current liabilities | 10 | 9 | 16 | 9 | 7 | |
| Deferred revenue, non-current | 4 | 3 | 3 | 1 | 2 | |
| Operating lease liabilities, non-current | — | 2,000 | 2 | 2 | 2 | |
| Total liabilities | 14 | 12 | 21 | 12 | 11 | |
| Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,781,774 shares issued and outstanding as of December 31, 2025, and 12,709,860 shares issued and outstanding as of December 31, 2024 | 1,000 | 1,000 | 1,265 | 1,259 | 1,254 | |
| Additional paid-in capital | 30 | 30 | 28 | 26 | 25 | |
| Retained earnings | 64 | 57 | 43 | 47 | 47 | |
| Total stockholders' equity | 95 | 87 | 71 | 74 | 72 | |
| Total liabilities and stockholders' equity | 109 | 98 | 92 | 86 | 83 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net income | 22 | 19 | 17 | 13 | 9 | |
| Allowance for credit losses | −84,000 | −95,000 | 208,337 | 102,767 | 13,876 | |
| Provision for excess and obsolete inventory | 47,000 | 88,000 | 181,443 | 55,737 | 118,217 | |
| Depreciation & amortization | 1 | 818,000 | 765,180 | 670,673 | 1 | |
| Loss on disposal of property and equipment | 37,000 | 4,000 | 12,537 | −1,741 | 5,544 | |
| Stock-based compensation | 3 | 3 | 2 | 1 | 1 | |
| Deferred income taxes, net | 3 | −698,000 | −1 | 57,097 | 523,607 | |
| Accounts receivable | −3 | 2 | 841,911 | −8 | −575,543 | |
| Inventory | −1 | 3 | −7 | −1 | −393,316 | |
| Prepaid income taxes | −3 | −786,000 | — | — | — | |
| Prepaid expenses and other current assets | −132,000 | −320,000 | −562,487 | 305,936 | −1 | |
| Other assets | −40,000 | −17,000 | 467,223 | −398,224 | 26,557 | |
| Accounts payable | −76,000 | −862,000 | −216,436 | 1 | 30,414 | |
| Accrued payroll and benefits | −554,000 | 997,000 | −96,787 | 57,330 | 1 | |
| Other accrued taxes | 150,000 | 60,000 | −18,678 | −18,396 | 36,334 | |
| Warranty reserve | 26,000 | 1,000 | 23,433 | −14,850 | 18,826 | |
| Deferred revenue | 2 | −111,000 | 615,636 | 530,576 | 48,062 | |
| Other current liabilities | −150,000 | −100,000 | 250,000 | −146,435 | — | |
| Accrued income taxes | 2 | −786,051 | 254,093 | 3 | −829,227 | |
| Net cash provided by operating activities | 25 | 26 | 13 | 10 | 11 | |
| Purchases of property and equipment | −8 | −8 | −7 | −823,019 | −482,325 | |
| Capitalized intangible assets | −656,000 | −812,000 | −566,657 | −1 | −259,434 | |
| Net cash used in investing activities | −8 | −9 | −8 | −1 | 648,241 | |
| Dividends paid | −15 | −14 | −13 | −13 | — | |
| Proceeds from exercises of stock options | — | 29,000 | 176,744 | 146,708 | 623,242 | |
| Taxes paid related to the net share settlement of equity awards | −3 | −688,000 | −610,348 | −293,981 | −598,817 | |
| Net cash used in financing activities | −18 | −14 | −14 | −13 | 24,425 | |
| Net (decrease) increase in cash and cash equivalents | −1 | 2 | −8 | −4 | 12 | |
| Cash paid for income taxes | 4 | 7 | 5 | 2 | 970,000 | |
| ROU asset and liability adjustment | — | 1 | — | — | — | |
| Operating and short-term lease payments recorded within cash flow provided by operating activities | 489,000 | 817,000 | 675,190 | 534,469 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is IRADIMED CORP's CIK number?
IRADIMED CORP's SEC CIK number is 0001325618 (1325618). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find IRADIMED CORP's SEC filings?
All of IRADIMED CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did IRADIMED CORP last report earnings?
IRADIMED CORP (IRMD) most recently filed an earnings 8-K with the SEC on May 1, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-029125). This is IRADIMED CORP's most recent earnings filing of record — not a forecast of its next earnings date.
What is IRADIMED CORP's most recent earnings 8-K?
IRADIMED CORP's latest earnings 8-K (Item 2.02) was filed May 1, 2026 under accession 0001628280-26-029125. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View IRADIMED CORP's latest earnings 8-K →
Look up any company's CIK number →